SG10201914126RA - Anti-ox40 antibodies and their uses - Google Patents

Anti-ox40 antibodies and their uses

Info

Publication number
SG10201914126RA
SG10201914126RA SG10201914126RA SG10201914126RA SG10201914126RA SG 10201914126R A SG10201914126R A SG 10201914126RA SG 10201914126R A SG10201914126R A SG 10201914126RA SG 10201914126R A SG10201914126R A SG 10201914126RA SG 10201914126R A SG10201914126R A SG 10201914126RA
Authority
SG
Singapore
Prior art keywords
antibodies
making
methods
nucleic acids
acids encoding
Prior art date
Application number
SG10201914126RA
Other languages
English (en)
Inventor
Fiona A Harding
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of SG10201914126RA publication Critical patent/SG10201914126RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201914126RA 2016-12-15 2017-12-15 Anti-ox40 antibodies and their uses SG10201914126RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662434761P 2016-12-15 2016-12-15

Publications (1)

Publication Number Publication Date
SG10201914126RA true SG10201914126RA (en) 2020-02-27

Family

ID=60937946

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201914126RA SG10201914126RA (en) 2016-12-15 2017-12-15 Anti-ox40 antibodies and their uses

Country Status (36)

Country Link
US (7) US10556962B2 (ru)
EP (2) EP3725809A1 (ru)
JP (2) JP6772385B2 (ru)
KR (2) KR20210157471A (ru)
CN (1) CN110573527A (ru)
AR (1) AR110526A1 (ru)
AU (1) AU2017377036B2 (ru)
BR (2) BR122020025629B1 (ru)
CA (1) CA3045940A1 (ru)
CL (1) CL2019001646A1 (ru)
CO (1) CO2019007288A2 (ru)
CR (1) CR20190330A (ru)
CY (1) CY1123274T1 (ru)
DK (1) DK3504242T3 (ru)
DO (1) DOP2019000165A (ru)
EC (1) ECSP19050049A (ru)
ES (1) ES2813057T3 (ru)
HR (1) HRP20201259T1 (ru)
HU (1) HUE050399T2 (ru)
IL (1) IL267070A (ru)
LT (1) LT3504242T (ru)
MA (1) MA53184A (ru)
MX (1) MX2019007121A (ru)
MY (1) MY198059A (ru)
PE (1) PE20191403A1 (ru)
PH (1) PH12019501357A1 (ru)
PL (1) PL3504242T3 (ru)
PT (1) PT3504242T (ru)
RS (1) RS60664B1 (ru)
RU (1) RU2753493C2 (ru)
SG (1) SG10201914126RA (ru)
SI (1) SI3504242T1 (ru)
TW (1) TWI734879B (ru)
UA (1) UA125041C2 (ru)
UY (1) UY37523A (ru)
WO (1) WO2018112346A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2813057T3 (es) * 2016-12-15 2021-03-22 Abbvie Biotherapeutics Inc Anticuerpos anti-ox40 y sus usos
US20200181275A1 (en) * 2017-06-09 2020-06-11 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
WO2019028182A2 (en) * 2017-08-01 2019-02-07 Remd Biotherapeutics, Inc. TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40)
CN110790837A (zh) * 2018-08-02 2020-02-14 上海君实生物医药科技股份有限公司 抗btla抗体
WO2020119789A1 (en) * 2018-12-14 2020-06-18 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing the same, and use thereof
JP7346576B2 (ja) * 2018-12-25 2023-09-19 ハンクス バイオファーマシューティクス，インコーポレイテッド 抗ｏｘ４０モノクローナル抗体とその応用
CN110172090B (zh) * 2019-06-03 2020-04-03 中山标佳生物科技有限公司 Cd134单克隆抗体及其制备方法和癌症治疗中的应用
WO2021098851A1 (en) * 2019-11-20 2021-05-27 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4/ox40 bispecific antibodies and uses thereof
CA3162705A1 (en) 2019-12-17 2021-06-24 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
CN113045654A (zh) * 2019-12-27 2021-06-29 南开大学 抗ox40抗体及其用途
CN111303285B (zh) * 2019-12-27 2023-06-02 百力司康生物医药(杭州)有限公司 靶向ox40的抗体及其制备方法和应用
US20230139700A1 (en) * 2020-03-23 2023-05-04 Bio-Thera Solutions, Ltd. Development and application of immune cell activator
US20230295324A1 (en) * 2020-06-30 2023-09-21 Harbour Biomed (Shanghai) Co., Ltd Ox40-targeted antibody, and preparation method therefor and application thereof
CN111704671B (zh) * 2020-08-19 2020-11-24 广东赛尔生物科技有限公司 Ox40抗体及其在治疗癌症中的应用
CN112442121A (zh) * 2020-08-20 2021-03-05 山东兴瑞生物科技有限公司 Ox40抗体、其编码基因、及抗体的制备方法和在增强人体免疫功能中的应用
CN114106173A (zh) * 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 抗ox40抗体、其药物组合物及应用
CN111763258B (zh) * 2020-09-01 2020-12-29 北京百奥赛图基因生物技术有限公司 抗ox40抗体及其用途
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
CN115260312A (zh) * 2021-04-30 2022-11-01 保诺科技（北京）有限公司 结合ox40的抗体或抗原结合片段

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
ATE408011T1 (de) 1998-02-24 2008-09-15 Sisters Of Providence In Orego Zusammensetzungen, die entweder ein ox-40- rezeptor-bindemittel oder eine für ein solches bindemittel kodierende nukleicsäuresequenz enthalten, und verfahren zur verbesserung der antigenspezifischen immunantwort
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2489004C (en) 2002-06-13 2013-01-08 Crucell Holland B.V. Agonistic binding molecules to the human ox40 receptor
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US20080286286A1 (en) 2006-01-13 2008-11-20 Board Of Regents, The University Of Texas System Methods to Treat Disease States by Influencing the Signaling of Ox-40-Receptors and High Throughput Screening Methods for Identifying Substances Therefor
EP2851374B1 (en) 2007-12-14 2017-05-03 Bristol-Myers Squibb Company Binding molecules to the human OX40 receptor
DK2609118T3 (en) 2010-08-23 2017-04-03 Univ Texas Anti-OX40 antibodies and methods for their use
CN103946238B (zh) * 2011-08-23 2016-10-12 德克萨斯州立大学董事会 抗ox40抗体及使用其的方法
US20140377253A1 (en) 2013-03-15 2014-12-25 Abbvie Biotherapeutics Inc. Fc variants
PT2976361T (pt) * 2013-03-18 2018-10-19 Janssen Pharmaceuticals Inc Anticorpos anti-cd134 (ox40) humanizados e utilizações dos mesmos
BR112016022345A2 (pt) 2014-03-31 2017-10-10 Genentech Inc terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
MX2017005751A (es) 2014-11-03 2018-04-10 Genentech Inc Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
US10259882B2 (en) * 2015-05-07 2019-04-16 Agenus Inc. Anti-OX40 antibodies
MX2017014699A (es) * 2015-05-21 2018-04-11 Alligator Bioscience Ab Polipeptidos novedosos.
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
MA43389A (fr) 2015-12-02 2021-05-12 Agenus Inc Anticorps anti-ox40 et leurs procédés d'utilisation
ES2813057T3 (es) * 2016-12-15 2021-03-22 Abbvie Biotherapeutics Inc Anticuerpos anti-ox40 y sus usos

Also Published As

Publication number Publication date
HRP20201259T1 (hr) 2020-11-13
MA53184A (fr) 2021-05-26
US20200181282A1 (en) 2020-06-11
DOP2019000165A (es) 2019-07-15
UA125041C2 (uk) 2021-12-29
BR122020025629B1 (pt) 2022-05-31
CA3045940A1 (en) 2018-06-21
TWI734879B (zh) 2021-08-01
WO2018112346A1 (en) 2018-06-21
RU2019121895A3 (ru) 2021-02-15
RU2019121895A (ru) 2021-01-15
AU2017377036A1 (en) 2019-07-11
PH12019501357A1 (en) 2020-01-20
US10040864B2 (en) 2018-08-07
KR102341926B1 (ko) 2021-12-23
PE20191403A1 (es) 2019-10-04
CY1123274T1 (el) 2021-12-31
US20180194855A1 (en) 2018-07-12
CL2019001646A1 (es) 2019-08-23
ES2813057T3 (es) 2021-03-22
CO2019007288A2 (es) 2019-08-20
TW201825520A (zh) 2018-07-16
AR110526A1 (es) 2019-04-10
EP3504242A1 (en) 2019-07-03
KR20210157471A (ko) 2021-12-28
US20210017289A1 (en) 2021-01-21
MY198059A (en) 2023-07-31
LT3504242T (lt) 2020-09-10
IL267070A (en) 2019-08-29
US10604584B2 (en) 2020-03-31
US20220112304A1 (en) 2022-04-14
PT3504242T (pt) 2020-08-26
RU2753493C2 (ru) 2021-08-17
US20200048363A1 (en) 2020-02-13
DK3504242T3 (da) 2020-08-17
ECSP19050049A (es) 2019-07-31
BR112019012328A2 (pt) 2019-11-19
EP3725809A1 (en) 2020-10-21
SI3504242T1 (sl) 2020-10-30
CN110573527A (zh) 2019-12-13
EP3504242B1 (en) 2020-06-24
UY37523A (es) 2018-07-31
JP2020504101A (ja) 2020-02-06
MX2019007121A (es) 2020-02-05
RS60664B1 (sr) 2020-09-30
US20180346593A1 (en) 2018-12-06
CR20190330A (es) 2019-12-19
US10556962B2 (en) 2020-02-11
JP2021019603A (ja) 2021-02-18
HUE050399T2 (hu) 2020-12-28
KR20190092552A (ko) 2019-08-07
AU2017377036B2 (en) 2022-06-23
US20180171023A1 (en) 2018-06-21
JP6772385B2 (ja) 2020-10-21
PL3504242T3 (pl) 2020-11-16

Similar Documents

Publication Publication Date Title
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
PH12019502283A1 (en) Anti-lag3 antibodies
ZA202107931B (en) Anti-tau antibodies and methods of use
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MX2019007020A (es) Anticuerpos il-11.
MX2019007021A (es) Anticuerpos il-11ra.
SG10201803042PA (en) Anti-tim-3 antibodies
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MX2019006330A (es) Anticuerpos anti-tau y metodos de uso.
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
MX2023006415A (es) Anticuerpos, usos y metodos.
MX2018012176A (es) Anticuerpos anti-factor bb del complemento y usos de estos.
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
MX2018009218A (es) Anticuerpos de cgrp y sus usos.